Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B C Cho

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
British Journal of Cancer|November 16, 2006
A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimensH-C Jeung, S Y Rha, B C Cho, et al.
Cell|October 5, 1990
Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel allelesN G Copeland, D J Gilbert, B C Cho, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2011
Tumor regression and positional changes in non-small cell lung cancer during radical radiotherapyGerald Lim, Andrea Bezjak, Jane Higgins, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2025
Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinibH Horinouchi, B C Cho, D R Camidge, et al.
Oncogene|September 26, 2017
ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinomaM R Yun, H M Choi, H N Kang, et al.
ESMO Open|September 24, 2025
BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter studyP Schöffski, A Gazzah, J Trigo, et al.
Radiation Oncology (London, England)|September 13, 2017
Risk for surgical complications after previous stereotactic body radiotherapy of the spineJohannes Roesch, John B C Cho, Daniel K Fahim, et al.
Oncogenesis|July 19, 2016
Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapyS-M Kim, H Kim, M R Yun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 2020
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapyS Park, M-H Lee, M Seong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2009
Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancerJon-Paul J Voroney, Andrew Hope, Max R Dahele, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
British Journal of Cancer|November 16, 2006
A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimensH-C Jeung, S Y Rha, B C Cho, et al.
Cell|October 5, 1990
Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel allelesN G Copeland, D J Gilbert, B C Cho, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2011
Tumor regression and positional changes in non-small cell lung cancer during radical radiotherapyGerald Lim, Andrea Bezjak, Jane Higgins, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2025
Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinibH Horinouchi, B C Cho, D R Camidge, et al.
Oncogene|September 26, 2017
ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinomaM R Yun, H M Choi, H N Kang, et al.
ESMO Open|September 24, 2025
BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter studyP Schöffski, A Gazzah, J Trigo, et al.
Radiation Oncology (London, England)|September 13, 2017
Risk for surgical complications after previous stereotactic body radiotherapy of the spineJohannes Roesch, John B C Cho, Daniel K Fahim, et al.
Oncogenesis|July 19, 2016
Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapyS-M Kim, H Kim, M R Yun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 2020
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapyS Park, M-H Lee, M Seong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2009
Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancerJon-Paul J Voroney, Andrew Hope, Max R Dahele, et al.
Pageof 8